# Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

> **NCT03760523** · PHASE1 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 27 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Minnelide

## Key facts

- **NCT ID:** NCT03760523
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-18
- **Primary completion:** 2023-10-09
- **Final completion:** 2023-10-09
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Toxicity -Two DLT events occurred
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03760523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03760523, "Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03760523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*